Reuters logo
Sanofi's diabetes drug Lyxumia approved in Europe
February 4, 2013 / 6:16 AM / 5 years ago

Sanofi's diabetes drug Lyxumia approved in Europe

PARIS, Feb 4 (Reuters) - Sanofi said on Monday regulators have approved Lyxumia, a diabetes treatment, for sale in the 27 member states of Europe.

The drug, also known by its generic name lixisenatide, is an injectable to be taken once a day in conjuction with other drugs or insulin by patients who are otherwise not able to control their blood sugar levels.

Reporting by Leila Abboud; editing by Blaise Robinson

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below